Human Genome Epidemiology (HuGE) Review Genotype Misclassification in Genetic Association Studies of the rs1042522 TP53 (Arg72Pro) Polymorphism: A Systematic Review of Studies of Breast, Lung, Colorectal, Ovarian, and Endometrial Cancer

s. BMCMed Inform Decis Mak. 2007;7:17.23. Hainaut P, Hernandez T, Robinson A, et al. IARC database ofp53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools.Nucleic Acids Res. 1998;26(1):205–213. 24. Hainaut P, Soussi T, Shomer B, et al. Database of p53 genesomatic mutations in human tumors and cell lines: updatedcompilation and future prospects. Nucleic Acids Res. 1997; 25(1):151–157.25. Hamroun D, Kato S, Ishioka C, et al. The UMD TP53 database and website: update and revisions. Hum Mutat.2006;27(1):14–20.26. Beroud C, Soussi T. The UMD-p53 database: new mutations and analysis tools. Hum Mutat. 2003;21(3):176–181.27. Zou G, Zhao H. The impacts of errors in individual genotyping and DNA pooling on association studies. GenetEpidemiol. 2004;26(1):1–10.28. Jawaid A, Sham P. Impact and quantification of the sources of error in DNA pooling designs. Ann Hum Genet. 2009;73(1):118–124. 29. Smith TC, Spiegelhalter DJ, Thomas A. Bayesian approachesto random effects meta analysis: a comparative study. StatMed. 1995;14(24):2685–2699. 30. Gelman A, Hill J. Multilevel generalized linear models. In: Data Analysis Using Regression and Multilevel/Hierarchical Models. Cambridge, United Kingdom: Cambridge University Press; 2007:325–342.31. Spiegelhalter D, Abrams K, Myles J. Evidence synthesis. In: Bayesian Approaches to Clinical Trials and Health-Care Evaluation. Chichester, United Kingdom: John Wiley & SonsLtd; 2004:267–303. 32. Turner RM, Omar RZ, Yang M, et al. A multilevel modelframework for meta-analysis of clinical trials with binary outcomes. Stat Med. 2000;19(24):3417–3432.33. DerSimonian R, Laird N. Meta-analysis in clinical trials.Control Clin Trials. 1986;7(3):177–188. 34. Higgins J, Thompson SG, Spiegelhalter DJ. A re-evaluation ofrandom-effects meta-analysis. J R Stat Soc Ser A Stat Soc. 2009;172(1):137–159.1324 Dahabreh et al. Am J Epidemiol. 2013;177(12):1317–1325 35. Cochran W. The combination of estimates fromdifferent experiments. Biometrics. 1954;10(1):101–129. 36. Higgins JP, Thompson SG. Quantifying heterogeneity in ameta-analysis. Stat Med. 2002;21(11):1539–1558. 37. Thompson SG, Higgins JP. How should meta-regressionanalyses be undertaken and interpreted? Stat Med. 2002;21(11):1559–1573. 38. Knapp G, Hartung J. Improved tests for a random effects meta-regression with a single covariate. Stat Med. 2003;22(17):2693–2710. 39. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med. 2006;25(20):3443–3457.40. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629–634.41. Lau J, Ioannidis JP, Terrin N, et al. The case of the misleading funnel plot. BMJ. 2006;333(7568):597–600.42. Mantel N, Haenszel W. Statistical aspects of the analysis ofdata from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–748.43. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1(1):43–46.44. Nelson HH, Wilkojmen M, Marsit CJ, et al. TP53 mutation,allelism and survival in non-small cell lung cancer. Carcinogenesis. 2005;26(10):1770–1773.45. Papadakis E, Soulitzis N, Spandidos D. Association of p53codon 72 polymorphism with advanced lung cancer: theArg allele is preferentially retained in tumours arising in Arg/ Pro germline heterozygotes. Br J Cancer. 2002;87(9):1013–1018. 46. Furihata M, Takeuchi T, Matsumoto M, et al. p53 mutationarising in Arg72 allele in the tumorigenesis and developmentof carcinoma of the urinary tract. Clin Cancer Res. 2002; 8(5):1192–1195.47. Bonafe M, Ceccarelli C, Farabegoli F, et al. Retention of thep53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/prolineheterozygous breast cancer patients. Clin Cancer Res. 2003; 9(13):4860–4864.48. Kawaguchi H, Ohno S, Araki K, et al. p53 polymorphism inhuman papillomavirus-associated esophageal cancer. Cancer Res. 2000;60(11):2753–2755.49. Dai S, Mao C, Jiang L, et al. P53 polymorphism and lung cancer susceptibility: a pooled analysis of 32 case-controlstudies. Hum Genet. 2009;125(5):633–638.50. Matakidou A, Eisen T, Houlston R. TP53 polymorphisms and lung cancer risk: a systematic review and meta analysis.Mutagenesis. 2003;18(4):377–385. 51. Lawlor DA, Harbord RM, Sterne JA, et al. Mendelianrandomization: using genes as instruments for makingcausal inferences in epidemiology. Stat Med. 2008;27(8): 1133–1163.Genotype Misclassification in Studies of TP53 Arg72Pro 1325 Am J Epidemiol. 2013;177(12):1317–1325